Latest & greatest articles for irritable bowel syndrome

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for irritable bowel syndrome

1. Irritable bowel syndrome

Irritable bowel syndrome Irritable bowel syndrome - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Irritable bowel syndrome Last reviewed: December 2018 Last updated: January 2019 Summary Irritable bowel syndrome symptoms include recurrent abdominal pain or discomfort that is associated with a change in stool frequency or form. The pain or discomfort may be relieved by defecation. It is important to determine whether (...) be individualised and is dependent on the patient's predominant symptoms. Definition Irritable bowel syndrome (IBS) is a chronic condition characterised by abdominal pain associated with bowel dysfunction. The pain is often relieved by defecation and is sometimes accompanied by abdominal bloating. There are no structural abnormalities to explain the pain. IBS occurs in about 15% of the adult population. The aetiology is probably multi-factorial and evidence suggests motility, inflammatory, genetic, immune

2019 BMJ Best Practice

2. Durability and Decay of Treatment Benefit of Cognitive Behavioral Therapy for Irritable Bowel Syndrome: 12-Month Follow-Up

Durability and Decay of Treatment Benefit of Cognitive Behavioral Therapy for Irritable Bowel Syndrome: 12-Month Follow-Up 30429592 2018 11 22 1572-0241 2018 Nov 14 The American journal of gastroenterology Am. J. Gastroenterol. Durability and Decay of Treatment Benefit of Cognitive Behavioral Therapy for Irritable Bowel Syndrome: 12-Month Follow-Up. 10.1038/s41395-018-0396-x There is a need for safe and effective IBS treatments that provide immediate and sustained improvement of IBS symptoms (...) , particularly among more severe patients. The aim was to assess long-term clinical response of cognitive behavioral therapy (CBT) with reference to IBS education. A total of 436 Rome III-diagnosed IBS patients (80% F, M age = 41 years) were randomized to: 4 session home-based CBT (minimal contact (MC-CBT)), 10 session clinic-based CBT (standard (S-CBT)), or 4 session IBS education (EDU). Follow-up occurred at 2 weeks and 3, 6, 9, and 12 months following treatment completion. Treatment response was based

2018 EvidenceUpdates

3. Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis

Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis 30177784 2018 09 04 1572-0241 2018 Sep 03 The American journal of gastroenterology Am. J. Gastroenterol. Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis. 10.1038/s41395-018-0222-5 Irritable bowel syndrome (IBS) is a chronic functional bowel disorder that is thought to be due (...) to a disorder of brain-gut function. Drugs acting centrally, such as antidepressants, and psychological therapies may, therefore, be effective. We updated a previous systematic review and meta-analysis of randomized controlled trials (RCTs). MEDLINE, EMBASE, PsychINFO, and the Cochrane Controlled Trials Register were searched (up to July 2017). Trials recruiting adults with IBS, which compared antidepressants versus placebo, or psychological therapies versus control therapy or "usual management" were

2018 EvidenceUpdates

4. Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome

Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome 30108163 2018 08 15 1468-3288 2018 Aug 14 Gut Gut Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. gutjnl-2017-315136 10.1136/gutjnl-2017-315136 More effective treatments are needed for patients with postinfectious, diarrhoea-predominant, irritable bowel syndrome (IBS-D). Accordingly, we conducted a randomised, double (...) -blind, placebo-controlled, 8-week-long trial to assess the efficacy and safety of oral glutamine therapy in patients who developed IBS-D with increased intestinal permeability following an enteric infection. Eligible adults were randomised to glutamine (5 g/t.i.d.) or placebo for 8 weeks. The primary end point was a reduction of ≥50 points on the Irritable Bowel Syndrome Severity Scoring System (IBS-SS). Secondary endpoints included: raw IBS-SS scores, changes in daily bowel movement frequency

2018 EvidenceUpdates

5. Irritable bowel syndrome

Irritable bowel syndrome Top results for irritable bowel syndrome - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search (...) box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for irritable bowel syndrome The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic

2018 Trip Latest and Greatest

6. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study

Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study 29980607 2018 08 05 1468-3288 2018 Jul 06 Gut Gut Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. gutjnl-2018-316434 10.1136/gutjnl-2018-316434 IBS is associated with an intestinal dysbiosis and faecal microbiota (...) transplantation (FMT) has been hypothesised to have a positive effect in patients with IBS. We performed a randomised, double-blind placebo-controlled trial to investigate if FMT resulted in an altered gut microbiota and improvement in clinical outcome in patients with IBS. We performed this study in 52 adult patients with moderate-to-severe IBS. At the screening visit, clinical history and symptoms were assessed and faecal samples were collected. Patients were randomised to FMT or placebo capsules for 12

2018 EvidenceUpdates

7. A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome

A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome 30046155 2018 07 26 1572-0241 2018 Jul 26 The American journal of gastroenterology Am. J. Gastroenterol. A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome. 10.1038/s41395-018-0195-4 Dietary triggers such as gluten and highly fermentable (...) oligo-, di- and monosaccharides and polyols (FODMAP)-containing foods have been associated with worsening irritable bowel syndrome (IBS) symptoms. However, the true impact of dietary restriction on IBS symptoms has remained unclear. The aim of this study was to conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) examining the efficacy of exclusion diets (we focused on low FODMAP and gluten-free diets (GFD)) in IBS. We conducted a search of the literature using

2018 EvidenceUpdates

8. Irritable bowel syndrome

Irritable bowel syndrome Autosynthesis - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) to (we will only get better by constructive feedback). For a list of known issues . Also read , explaining issues with the system. To get started, type a condition/disease into the search box above. Here are some examples to get you started: Performing Autosynthesis X Axis Alphabetically Risk of bias No. Articles Sample Size Risk of bias any low Minimum sample size Apply Follow us: © 2017 Trip Database Ltd. company number 04316414. Trip is proud to be made in the UK.

2018 Trip Evidence Maps

9. Naturopathic approaches to irritable bowel syndrome: protocol for a prospective observational study in academic teaching clinics (PubMed)

Naturopathic approaches to irritable bowel syndrome: protocol for a prospective observational study in academic teaching clinics 30271717 2018 11 14 2213-4220 7 3 2018 Sep Integrative medicine research Integr Med Res Naturopathic approaches to irritable bowel syndrome: protocol for a prospective observational study in academic teaching clinics. 279-286 10.1016/j.imr.2018.06.001 Irritable bowel syndrome (IBS) is a common functional bowel disorder with a worldwide prevalence estimated between 10 (...) % and 20%. It has a significant impact on quality of life and societal expense. While there are pharmaceutical options available, few can be reliably recommended. Many IBS sufferers turn to complementary and alternative medicine including naturopathy. Naturopathic approaches to IBS are poorly studied to date. We aim to describe naturopathic approaches to IBS as well as establish pilot data on before and after changes in validated IBS instruments. The study will employ a multi-centered, international

Full Text available with Trip Pro

2018 Integrative medicine research

10. Eluxadoline (Viberzi) - irritable bowel syndrome with diarrhea (IBS-D)

Eluxadoline (Viberzi) - irritable bowel syndrome with diarrhea (IBS-D) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Summary Basis of Decision (SBD) for Contact: Summary basis of decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent activity SBDs written for approved after September 1

2018 Health Canada - Drug and Health Product Register

11. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials

Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials 29545635 2018 03 16 1572-0241 2018 Mar 15 The American journal of gastroenterology Am. J. Gastroenterol. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. 10.1038/s41395-018-0026-7 Two identical, phase 3, randomized, double (...) -blind, placebo-controlled trials evaluated the efficacy and safety of plecanatide in patients with irritable bowel syndrome with constipation (IBS-C). Adults meeting Rome III criteria for IBS-C were randomized (1:1:1) to placebo or plecanatide (3 or 6 mg) for 12 weeks. The primary efficacy end point was the percentage of overall responders (patients reporting ≥30% reduction from baseline in worst abdominal pain plus an increase of ≥1 complete spontaneous bowel movement (CSBM)/week from baseline

Full Text available with Trip Pro

2018 EvidenceUpdates

13. Irritable bowel syndrome

Irritable bowel syndrome Irritable bowel syndrome - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Irritable bowel syndrome Last reviewed: August 2018 Last updated: July 2018 Summary Irritable bowel syndrome symptoms include recurrent abdominal pain or discomfort that is associated with a change in stool frequency or form. The pain or discomfort may be relieved by defecation. It is important to determine whether (...) be individualised and is dependent on the patient's predominant symptoms. Definition Irritable bowel syndrome (IBS) is a chronic condition characterised by abdominal pain associated with bowel dysfunction. The pain is often relieved by defecation and is sometimes accompanied by abdominal bloating. There are no structural abnormalities to explain the pain. IBS occurs in about 15% of the adult population. The aetiology is probably multi-factorial and evidence suggests motility, inflammatory, genetic, immune

2018 BMJ Best Practice

14. Self-Perception of Iranian Patients during their life with Irritable Bowel Syndrome: A Qualitative Study (PubMed)

Self-Perception of Iranian Patients during their life with Irritable Bowel Syndrome: A Qualitative Study Electronic Physician (ISSN: 2008-5842) http://www.ephysician.ir December 2017, Volume: 9, Issue: 12, Pages: 5885-5893, DOI: http://dx.doi.org/10.19082/5885 Corresponding author: Professor Dr. Farkhondeh Sharif, Community Based Psychiatric Care Research Center, Shiraz Geriatric Research Center, Department of Mental Health and Psychiatric Nursing, School of Nursing and Midwifery, Shiraz (...) work is properly cited, the use is non-commercial and no modifications or adaptations are made. Page 5885 Self-Perception of Iranian Patients during their life with Irritable Bowel Syndrome: A Qualitative Study Zinat Mohebbi 1 , Farkhondeh Sharif 2 , Hamid Peyrovi 3 , Mahnaz Rakhshan 4 , Mahvash Alizade Naini 5 , Ladan Zarshenas 6 1 Ph.D. Candidate of Nursing, Faculty Member, Student Research Committee, Department of Medical Surgical Nursing, School of Nursing and Midwifery, Shiraz University

Full Text available with Trip Pro

2017 Electronic physician

15. A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial

A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial 28625832 2017 10 16 2017 10 16 1528-0012 153 4 2017 Oct Gastroenterology Gastroenterology A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial. 936-947 S0016-5085(17)35744-X 10.1053/j.gastro.2017.06.010 Dietary restriction (...) of fermentable carbohydrates (a low FODMAP diet) has been reported to reduce symptoms in some patients with irritable bowel syndrome (IBS). We performed a randomized, placebo-controlled study to determine its effects on symptoms and the fecal microbiota in patients with IBS. We performed a 2×2 factorial trial of 104 patients with IBS (18-65 years old), based on the Rome III criteria, at 2 hospitals in the United Kingdom. Patients were randomly assigned (blinded) to groups given counselling to follow a sham

Full Text available with Trip Pro

2017 EvidenceUpdates

16. Eluxadoline for treating irritable bowel syndrome with diarrhoea

Eluxadoline for treating irritable bowel syndrome with diarrhoea Eluxadoline for treating irritable bowel Eluxadoline for treating irritable bowel syndrome with diarrhoea syndrome with diarrhoea T echnology appraisal guidance Published: 30 August 2017 nice.org.uk/guidance/ta471 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent (...) inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Eluxadoline for treating irritable bowel syndrome with diarrhoea (TA471) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 24Contents Contents 1 Recommendations 4 2 The technology 5 3

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

17. Effects of a Low FODMAP Diet and Specific Carbohydrate Diet on Symptoms and Nutritional Adequacy of Patients with Irritable Bowel Syndrome: Preliminary Results of a Single-blinded Randomized Trial (PubMed)

Effects of a Low FODMAP Diet and Specific Carbohydrate Diet on Symptoms and Nutritional Adequacy of Patients with Irritable Bowel Syndrome: Preliminary Results of a Single-blinded Randomized Trial 28721345 2018 11 13 2450-131X 5 2 2017 Jun Journal of translational internal medicine J Transl Int Med Effects of a Low FODMAP Diet and Specific Carbohydrate Diet on Symptoms and Nutritional Adequacy of Patients with Irritable Bowel Syndrome: Preliminary Results of a Single-blinded Randomized Trial (...) . 120-126 10.1515/jtim-2017-0004 IBS is the most common functional disease of the low gastrointestinal tract. Recently, the interest towards a diet approach has increased, for example, a diet with low content of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs). The aim of the present study is to evaluate the efficacy of a low FODMAP diet and a specific carbohydrate diet (SCD) conducted for 3 months on symptoms and to evaluate the deficiencies of vitamin D

Full Text available with Trip Pro

2017 Journal of translational internal medicine

18. Irritable Bowel Syndrome. (PubMed)

Irritable Bowel Syndrome. This issue provides a clinical overview of irritable bowel syndrome, focusing on diagnosis, treatment, and practice improvement. The content of In the Clinic is drawn from the clinical information and education resources of the American College of Physicians (ACP), including MKSAP (Medical Knowledge and Self-Assessment Program). Annals of Internal Medicine editors develop In the Clinic in collaboration with the ACP's Medical Education and Publishing divisions

2017 Annals of Internal Medicine

19. Home-Based Hypnotherapy Self-exercises vs Individual Hypnotherapy With a Therapist for Treatment of Pediatric Irritable Bowel Syndrome, Functional Abdominal Pain, or Functional Abdominal Pain Syndrome: A Randomized Clinical Trial

Home-Based Hypnotherapy Self-exercises vs Individual Hypnotherapy With a Therapist for Treatment of Pediatric Irritable Bowel Syndrome, Functional Abdominal Pain, or Functional Abdominal Pain Syndrome: A Randomized Clinical Trial 28346581 2017 03 27 2017 05 01 2168-6211 171 5 2017 May 01 JAMA pediatrics JAMA Pediatr Home-Based Hypnotherapy Self-exercises vs Individual Hypnotherapy With a Therapist for Treatment of Pediatric Irritable Bowel Syndrome, Functional Abdominal Pain, or Functional (...) Abdominal Pain Syndrome: A Randomized Clinical Trial. 470-477 10.1001/jamapediatrics.2017.0091 Individual gut-directed hypnotherapy (HT) is effective in pediatric irritable bowel syndrome (IBS) and functional abdominal pain or functional abdominal pain syndrome (FAP[S]). It is, however, unavailable to many children. To compare the effectiveness of HT by means of home-based self-exercises using a CD with that of individual HT (iHT) performed by qualified therapists. This noninferiority

Full Text available with Trip Pro

2017 EvidenceUpdates

20. Deciphering the pathophysiology of irritable bowel syndrome and functional gastrointestinal disorders—an alternative model for pathogenesis: cytokine controlled transepithelial multi-feedback loop (PubMed)

Deciphering the pathophysiology of irritable bowel syndrome and functional gastrointestinal disorders—an alternative model for pathogenesis: cytokine controlled transepithelial multi-feedback loop 28447053 2018 11 13 2415-1289 2 2017 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol Deciphering the pathophysiology of irritable bowel syndrome and functional gastrointestinal disorders-an alternative model for pathogenesis: cytokine controlled transepithelial multi (...) -feedback loop. 18 10.21037/tgh.2017.03.02 A working theoretical model for irritable bowel syndrome (IBS) and other functional gastrointestinal disorders (FGIDs) does not exist, hampered by the lack of any clear cut invention that address all symptom and signs of the disease. Reports of cessation of symptom and signs of both major types of IBS have been published using a non-systemic, topically active agent-high potency polymerized cross-linked sucralfate (HPPCLS). The unique clinical effect of this non

Full Text available with Trip Pro

2017 Translational gastroenterology and hepatology